Valeritas touts data for wearable insulin delivery device
Valeritas is touting data from its Verdict study of its V-Go Wearable Insulin Delivery device at the American Diabetes Association 79th Scientific Sessions in San Francisco.
The data showed that patients who had Type 2 diabetes and switch to V-Go from a basal insulin regimen had lower A1c levels without increasing the total daily dose of insulin.
“Insulin therapy is often intensified utilizing a stepwise approach of adding one injection at a time due to the increased burden and complexity associated with basal-bolus therapy,” Dr. Trisha Zeidan, principal investigator of the Verdict study, said in a press release. “Although this stepwise approach is well accepted, research demonstrates in one year, the majority of patients will require full basal-bolus therapy to manage their diabetes. In our experience, V-Go offers a straightforward way to intensify directly from basal to basal-bolus therapy and has been well accepted by patients and proven effective, which is conducive to patient self-management.”
There were 73 participants in the study with Type 2 diabetes who used the V-Go device and reported having an average reduction in A1c of -1.3 with 16% fewer prescribed concomitant medications. The study also reported a decrease in hypoglycemia levels from 23% to 19% of patients and severe hypoglycemia reductions from 10% to 3% of patients.
“V-Go allows patients requiring basal-bolus therapy to get the insulin they need when they need it without the burden of multiple daily injections,” said John Timberlake, president and CEO of Valeritas. “We strongly believe that V-Go can ease the transition to basal-bolus therapy and are pleased with the results of this study.”